Cognition Therapeutics (CGTX) announced that Mary Hamby, PhD will be co-hosting a precision medicine workshop at the Hanson Wade Neuroimmunology Drug Development Summit. The workshop will review methods of screening participants for clinical trials to ensure that the patients selected are most likely to benefit from treatment. Dr. Hamby will present an overview of the findings from Cognition’s Phase 2 ‘SHINE’ study of zervimesine in adults with mild-to-moderate Alzheimer’s disease. Participants with lower levels of a protein called p-tau217 at the beginning of the SHINE study experienced a robust response to zervimesine treatment. Specifically, these individuals with lower p-tau217 levels scored 95% better on the ADAS-Cog 11 scale and 108% better on the MMSE scale than did their counterparts on placebo.
